Table 3.
Search results of clinical trials in clinicaltrials.gov for selected treatments organized by treatment class.
| TREATMENT CLASS | GENERIC TREATMENT NAME | INVESTIGATIONAL/BRAND TREATMENT NAME | CLINICAL TRIALS IN WHICH TREATMENT MENTIONED*,† | CLINICAL TRIALS WITH TREATMENT MENTION INCLUDING PRO DATA† | CLINICAL TRIALS WITH PROs REVIEWED IN FULL‡ |
|---|---|---|---|---|---|
| Hormonal therapies for ER+ (n = 6) | Anastrozole | NCT01602380/Arimidex® | 51 | 9/51 | 1/9 |
| Everolimus | Afinitor®; Afinitor Disperz™ | 55 | 4/55 | 2/4 | |
| Exemestane | Aromasin®, FCE-24304 | 114 | 14/114 | 2/14 | |
| Fulvestrant | Faslodex®, ZD9238 | 74 | 4/74 | 1/4 | |
| Letrozole | DB01005/Femara® | 62 | 15/62 | 1/15 | |
| Tamoxifen | Tamoxifen citrate, Nolvadex®, Soltamox® | 193 | 19/193 | 1/19 | |
| Targeted agents for HER2+ (n = 4) | Lapatinib | Tyverb™, GW572016, GSK572016 | 86 | 10/86 | 5/10 |
| Pertuzumab | Perjeta®, 2C4 | 25 | 6/25 | 4/6 | |
| Trastuzumab emtansine | T-DM1, Kadcyla® | 18 | 2/18 | 1/2 | |
| Trastuzumab | Herceptin®, SU011248, Herclon™ | 223 | 13/223 | 1/13 | |
| Chemotherapies for ER−, PR−, and/or HER2− (n = 5) | Capecitabine | Xeloda® | 162 | 10/162 | 1/10 |
| Docetaxel | XRP6976, Taxotere®, Docefrez™ | 147 | 13/147 | 1/13 | |
| Doxorubicin | Doxorubicin hydrochloride, doxorubicin liposomal, doxorubicin hydrochloride liposomal, DB00997, Adriamycin® | 73 | 7/73 | 1/7 | |
| Gemcitabine | Gemzar®, LY188011, gemcitabine hydrochloride | 90 | 4/90 | 4/4 | |
| Paclitaxel | Taxol®, DB01229, Abraxane® | 209 | 12/209 | 0/12 | |
| CDK inhibitors for ER+, HER2− (n = 3) | Abemaciclib | LY2835219 | 5 | 5/5 | 5/5 |
| Palbociclib | PD-0332991-0054, Ibrance® | 19 | 5/19 | 4/5 | |
| Ribociclib | LEE011 | 8 | 3/8 | 2/3 | |
| Src inhibitors (n = 1) | Dasatinib | NSC-732517 | 10 | 2/10 | 1/2 |
| PI3K inhibitors (n = 4) | Alpelisib | BYL719 | 0 | 0/0 | 0/0 |
| Buparlisib | BKM120 | 1 | 1/1 | 0/1 | |
| Pictilisib | GDC-0941 | 3 | 0/3 | 0/0 | |
| Taselisib | GDC-0032 | 2 | 0/2 | 0/0 | |
| HDAC inhibitors (n = 1) | Entinostat | MS-275 | 4 | 0/4 | 0/0 |
| Total | 1,634 | 74/1,634 | 38/74 |
Notes:
*
Includes number of Phase 2 or 3 clinical trials with a breast cancer indication registered in clinicaltrials.gov database.
†
Counts not mutually inclusive.
‡
Clinical trials were excluded from final review if the study drug was not one of the 24 treatments on the a priori list and/or if the trials were not sponsored by the pharmaceutical industry.